GENOVIS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.6 SEK | +0.35% |
|
-7.44% | -45.00% |
| Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
| Feb. 15 | Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2023 | 158M 14.36M | Sales 2024 * | 160M 14.53M | Capitalization | 1.87B 170M |
|---|---|---|---|---|---|
| Net income 2023 | 61M 5.54M | Net income 2024 * | 41M 3.72M | EV / Sales 2023 | 20.7 x |
| Net cash position 2023 | 123M 11.19M | Net cash position 2024 * | 125M 11.33M | EV / Sales 2024 * | 10.9 x |
| P/E ratio 2023 |
55.3
x | P/E ratio 2024 * |
44.9
x | Employees | 37 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.42% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.35% | ||
| 1 week | -7.44% | ||
| Current month | -14.37% | ||
| 1 month | -7.74% | ||
| 3 months | -42.80% | ||
| 6 months | -24.74% | ||
| Current year | -45.00% |
1 week
27.20
30.35
1 month
27.2037.00
Current year
27.2053.80
1 year
27.2066.90
3 years
27.2090.00
5 years
15.6590.00
10 years
1.2690.00
| Managers | Title | Age | Since |
|---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-12-31 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 21-12-31 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 16-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 72 | 20-05-04 | |
| Director/Board Member | 63 | 18-12-31 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 13-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 28.6 | +0.35% | 152,807 |
| 24-04-17 | 28.5 | +2.70% | 265,741 |
| 24-04-16 | 27.75 | 0.00% | 151,620 |
| 24-04-15 | 27.75 | -8.72% | 204,699 |
| 24-04-12 | 30.4 | -1.62% | 101,818 |
Delayed Quote Nasdaq Stockholm, April 18, 2024 at 11:29 am EDT
More quotes
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
28.6
SEK
Average target price
55.5
SEK
Spread / Average Target
+94.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.00% | 170M | |
| -1.59% | 12.58B | |
| -17.62% | 6.82B | |
| -3.93% | 5.14B | |
| -6.68% | 4.22B | |
| +0.53% | 4.21B | |
| -48.27% | 3.47B | |
| +7.09% | 2.65B | |
| -13.71% | 2.25B | |
| -3.40% | 1.69B |
- Stock Market
- Equities
- GENO Stock
